Entrada Therapeutics (TRDA) Cash from Operations (2020 - 2026)

Entrada Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 41695000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 8.28% year-over-year to 41695000.0; the TTM figure through Mar 2026 stood at 131700000.0 (down 141.45% YoY), while the FY2025 annual figure was 128512000.0, down 209.24% from the prior year.
• Cash from Operations was 41695000.0 for Q1 2026 at Entrada Therapeutics, down from 32203000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 203399000.0 in Q1 2023 to a low of 41695000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 9749823.53 across 5 years, with a median of 27304000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 1068.98% in 2023, then tumbled 687.57% in 2024.
• A 5-year view of Cash from Operations shows it stood at 27304000.0 in 2022, then surged by 85.3% to 4013000.0 in 2023, then sank by 687.57% to 31605000.0 in 2024, then slipped by 1.89% to 32203000.0 in 2025, then dropped by 29.48% to 41695000.0 in 2026.
• The last three Cash from Operations figures came in at 41695000.0 (Q1 2026), 32203000.0 (Q4 2025), and 28313000.0 (Q3 2025), per Business Quant data.